Martin Friedlander
15Patents
7h-index
15Co-inventors
59Inventor score
Filing activity: May 30, 1997 → Sep 12, 2011
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7273844B2 | Tryptophanyl-tRNA synthetase-derived polypeptides useful for the regulation of angiogenesis | Emerging Cross-Sectional Technologies | 94 | Expired |
| US8017593B2 | Tryptophanyl-tRNA synthetase-derived polypeptides useful for the regulation of angiogenesis | Emerging Cross-Sectional Technologies | 90 | Active |
| US7476651B2 | Tryptophanyl-tRNA synthetase-derived polypeptides useful for the regulation of angiogenesis | Emerging Cross-Sectional Technologies | 90 | Active |
| US7413885B2 | Tryptophanyl-tRNA synthetase-derived polypeptides useful for the regulation of angiogenesis | Emerging Cross-Sectional Technologies | 90 | Active |
| US7528106B2 | Compositions and methods for treatment of neovascular diseases | Human Necessities | 86 | Expired |
| US7645736B2 | Integrin inhibitors for the treatment of eye diseases | Human Necessities | 16 | Active |
| US7648959B2 | Methods and compositions for the treatment of diseases of the eye | Human Necessities | 15 | Active |
| US7838290B2 | Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith | Human Necessities | 3 | Active |
| US7153501B2 | Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith | Human Necessities | 3 | Expired |
| US7053041B1 | Methods and compositions useful for inhibition of αvβ5mediated angiogenesis | Chemistry; Metallurgy | 3 | Expired |
| US8900567B2 | Treatment of cone cell degeneration with transfected lineage negative hematopoietic stem cells | Human Necessities | 1 | Active |
| US7419953B2 | Selective R-cadherin antagonist and methods | Human Necessities | 0 | Expired |
| US8796237B2 | Tryptophanyl-tRNA synthetase-derived polypeptides useful for the regulation of angiogenesis | Emerging Cross-Sectional Technologies | 0 | Active |
| US8163697B2 | Selective R-cadherin antagonists and methods | Human Necessities | 0 | Active |
| US7931891B2 | Isolated myeloid-like bone marrow cell populations and methods of treatment therewith | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.